drugset / Trial / NCT02249091
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Non-randomizedSequentialOpen-labelTreatment
Summary
Acute Myeloid Leukemia (AML) is currently treated with chemotherapy by combining several drugs with different ways of inhibiting the cell growth. In this trial, standard chemotherapeutics that have proven their effectiveness for years, Ara-C and Idarubicin, will be combined with a new drug called Selinexor. Selinexor inhibits the growth of cancer cells by keeping certain proteins in the nucleus which control the cell growth.
Timeline
- Start
- 2014-09
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg/m2 | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Background | Idarubicin | Small molecule | 10 mg/m2 | Intravenous |